Cardiac Dual‐Targeting Nanocatalysts for Heart Failure Therapy by Breaking the ROS–Inflammation Positive Feedback
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Haoyu Du und 10 weiteren Autor:innen. Beteiligte Einrichtung: Huiya Hospital of The First Affiliated Hospital of Sun Yat-sen University, National and Local United Engineering Lab of Druggability and New Drugs Ev…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Heart Failure, Inflammation. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Non-communicable Chronic Diseases-National Science, Technology Major Project, National Natural Science Foundation of China.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a global public health challenge closely associated with oxidative stress and immune dysregulation. However, current therapeutic strategies for HF generally lack specific targeting to cardiac tissue, and the high perfusion rate of the heart further exacerbates insufficient drug accumulation at lesion sites, thus compromising therapeutic efficacy. Inspired by the barb‐hook of Xanthium strumarium, Fe 3 O 4 @UiO‐66 is functionalized with tannic acid (TA) to obtain a dual‐target nanocatalyst, termed FUTA. In vitro, FUTA efficiently scavenges free radicals and eliminates superoxide anions and hydrogen peroxide through multiple enzyme‐like activities, thus alleviating the isoproterenol (ISO)‐induced increase in cellular reactive oxygen species (ROS) levels, restoring mitochondrial membrane potential, and alleviating pathological enlargement of cardiomyocytes. In vivo, FUTA accumulates selectively in injured myocardial tissue through external magnetic attraction and internal binding of TA to the cardiac extracellular matrix (ECM), exerting synergistic antioxidant and immunomodulatory effects, resulting in significant improvements in cardiac structure and function, as well as a reduction in fibrosis. These findings highlight the therapeutic potential of FUTA in alleviating myocardial injury through the coordinated regulation of metabolic and immune pathways, offering a promising material‐based strategy for HF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huiya Hospital of The First Affiliated Hospital of Sun Yat-sen University, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, H…
- Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratory for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guang…
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China.
- Guangdong Provincial Key Laboratory of Pathogenesis, Targeted Prevention and Treatment of Heart Disease, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)…
ORCID-Profile: Duanping Sun
Förderung
- Non-communicable Chronic Diseases-National Science
- Technology Major Project
- National Natural Science Foundation of China
- Guangzhou Basic and Applied Basic Research Project
- Guangdong Major Project of Basic
- Applied Basic Research
- Guangdong Provincial Special Support Program for Prominent Talents
- Guangdong Provincial Key Laboratory of Construction Foundation
Zitieren
APA
Du, H., Ma, D., Zhang, X., Yu, W., Lin, R., Lu, J., Yu, N., Sun, D., Zhu, P., Liu, P., & Qiu, S. (2026). Cardiac Dual‐Targeting Nanocatalysts for Heart Failure Therapy by Breaking the ROS–Inflammation Positive Feedback. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503020
Vancouver
Du H, Ma D, Zhang X, Yu W, Lin R, Lu J, et al. Cardiac Dual‐Targeting Nanocatalysts for Heart Failure Therapy by Breaking the ROS–Inflammation Positive Feedback. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503020
BibTeX
@article{Du2026,
author = {Du, Haoyu and Ma, Dinghu and Zhang, Xiaoyuan and Yu, Wenjing and Lin, Rongyuan and Lu, Jing and Yu, Na and Sun, Duanping and Zhu, Ping and Liu, Peiqing and Qiu, Shaopeng},
title = {Cardiac Dual‐Targeting Nanocatalysts for Heart Failure Therapy by Breaking the ROS–Inflammation Positive Feedback},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503020}
}
EUVIMED